{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"300 mg tabalumab (LY2127399) group administered BTZ IV or SC data were combined per protocol in some instances as BTZ was a supplemental therapy for participants."},"pointOfContact":{"organization":"Eli Lilly and Company","phone":"800-545-5979","title":"Chief Medical Officer"}}